Changes to MEOS and Barriers to Entry

EP: 1.No Successor to OCM Would Disappoint

EP: 2.CMMI Open to Feedback, but EOM Out of the Blue

EP: 3.Some Practices That Did Not Do OCM Are Applying

EP: 4.Seven Tumor Types: Pros and Cons

EP: 5.A Model That Is Built to “Win”

EP: 6.Addressing Health Equity and Social Needs

EP: 7.Is Five Years Long Enough?

Now Viewing

EP: 8.Changes to MEOS and Barriers to Entry

EP: 9.Small Practices and Dual Risk: Considerations and Approaches

EP: 10.Does Pooling Make Sense?

EP: 11.What Would You Change About the EOM?

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, takes the discussion where everyone wants it to go: MEOS payments. What will lower payments—from $160 per patient per month to $70 for most patients, and $100 for those dually eligible for Medicare and Medicaid, mean for practices? Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, highlights the lack of a copayment for patients as a plus of the EOM, and says it’s good there is extra revenue tied to caring for the Medicaid population. But Divers and Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, both express concern about the barrier to entry issue for practices that most need to try value-based care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, says that CMMI would benefit from broader thinking about rewarding practices for attending to the global cost of care. Divers also notes the effect that inflation has had on practices, as the cost of supplies has increased.